Approval · Notice of Compliance 34814 · 2025
CAELYX: Notice of Compliance 34814
Issued February 10, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34814
- Date
- February 10, 2025
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Replacement of a manufacturing site and/or manufactur er involving production
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CAELYX | Not yet assigned | — |
Medicinal ingredients
- DOXORUBICIN HYDROCHLORIDE 2 MG per ML